Pfizer licenses gene for possible AMD therapy

Article

New York-Pfizer Inc. has acquired the worldwide license to a novel human gene that could have the potential to treat neovascular age-related macular degeneration (AMD).

New York-Pfizer Inc. has acquired the worldwide license to a novel human gene that could have the potential to treat neovascular age-related macular degeneration (AMD).

Under the deal with Quark Biotech Inc., Pfizer will develop the gene, called RTP-801, and molecules that modify it, to treat wet AMD. Financial terms of the deal were not disclosed.

Quark Biotech, a Fremont, CA-based company with research facilities in Fremont and Israel, combines gene silencing and DNA microarray technology to identify target genes and proteins related to the cause or progression of a disease. It is working on potential treatments for dyslipidemia and fibrotic and ischemic diseases of the eye and kidneys, including diabetic retinopathy.

Related Videos
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Raj Chovatiya, MD, PhD
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
Aimee C. Talleur, MD, a physician at St. Jude Children’s Research Hospital
Pat Furlong, BSN, RN
© 2024 MJH Life Sciences

All rights reserved.